Merrimack Pharmaceuticals' attempt to buck the trend on IPOs ended in failure today. The developer, a 2011 Fierce 15 company, has 5 drugs in the clinic and reportedly scrapped its offering saying that market conditions prevented it from pushing ahead. Story